EYPT

SEC source: 0000899243-19-003415 · doc5.xml · nonDerivative · entry 1

EW Healthcare Partners, L.P. · CIK 0001612343 · 10% owner

EW Healthcare Partners-A, L.P. · CIK 0001736240 · 10% owner

Essex Woodlands Fund IX-GP, L.P. · CIK 0001652285 · 10% owner

Essex Woodlands IX, LLC · CIK 0001652286 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,903,956

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 40,283,255 shares held by EW Healthcare Partners L.P. ("EWHP") and 1,620,701 shares held by EW Healthcare Partners-A L.P. ("EWHP-A"). Essex Woodlands Fund IX-GP, L.P. ("Fund IX-GP") is the general partner of EWHP and EWHP-A, respectively. Essex Woodlands IX, LLC (the "General Partner") is the general partner of Fund IX-GP. The General Partner holds sole voting and dispositive power over the shares held by EWHP and EWHP-A. The managers of the General Partner are Martin P. Sutter, R. Scott Barry, Ronald Eastman (also a member of the Issuer's board of directors) and Petri Vainio (collectively, the "Managers"), and may exercise voting and investment control over the shares only by the majority action of the Managers.

F1 · ownership.direct: Includes 40,283,255 shares held by EW Healthcare Partners L.P. ("EWHP") and 1,620,701 shares held by EW Healthcare Partners-A L.P. ("EWHP-A"). Essex Woodlands Fund IX-GP, L.P. ("Fund IX-GP") is the general partner of EWHP and EWHP-A, respectively. Essex Woodlands IX, LLC (the "General Partner") is the general partner of Fund IX-GP. The General Partner holds sole voting and dispositive power over the shares held by EWHP and EWHP-A. The managers of the General Partner are Martin P. Sutter, R. Scott Barry, Ronald Eastman (also a member of the Issuer's board of directors) and Petri Vainio (collectively, the "Managers"), and may exercise voting and investment control over the shares only by the majority action of the Managers.

SEC source: 0000899243-18-024157 · doc4.xml · derivative · entry 2

Mazzo David J · CIK 0001334549 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 417

Underlying: Common Stock · 417 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents the right to receive one share of the common stock of EyePoint Pharmaceuticals, Inc. (the "Company").

F2 · derivative.expiration_date: Subsequent to the vesting of the deferred stock units, the deferred stock units will be settled in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.

SEC source: 0000899243-18-024157 · doc4.xml · derivative · entry 1

Mazzo David J · CIK 0001334549 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,667

Underlying: Common Stock · 1,667 shares

Expires 2028-09-06

SEC source: 0000899243-18-021374 · doc4.xml · derivative · entry 1

Price David · CIK 0001449336 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 385,000

Underlying: Common Stock · 385,000 shares

Expires 2028-08-01

F1 · derivative.exercise_date: The option to purchase will vest and become exercisable in three equal annual installments beginning August 1, 2019.

SEC source: 0000899243-18-018711 · doc4.xml · derivative · entry 3

Ross Leonard S · CIK 0001458753 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,334

Underlying: Common Stock · 6,666 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: On June 27, 2017, the reporting person was granted 20,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.

F2 · derivative.expiration_date: On June 27, 2017, the reporting person was granted 20,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.

SEC source: 0000899243-18-018711 · doc4.xml · nonDerivative · entry 2

Ross Leonard S · CIK 0001458753 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,762

F3 · shares: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the insider's exercise of his withholding right following the vesting of the restricted stock units.

SEC source: 0000899243-18-018711 · doc4.xml · nonDerivative · entry 1

Ross Leonard S · CIK 0001458753 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,666

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

SEC source: 0000899243-18-018707 · doc4.xml · derivative · entry 2

Lurker Nancy · CIK 0001450485 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 40,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: On December 15, 2017, the reporting person was granted 120,000 restricted stock units, vesting in three equal annual installments beginning June 27, 2018.

F2 · derivative.expiration_date: On December 15, 2017, the reporting person was granted 120,000 restricted stock units, vesting in three equal annual installments beginning June 27, 2018.

SEC source: 0000899243-18-018707 · doc4.xml · nonDerivative · entry 1

Lurker Nancy · CIK 0001450485 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 135,033

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

SEC source: 0000899243-18-018708 · doc4.xml · derivative · entry 2

Godshall Douglas Evan · CIK 0001404227 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: On December 15, 2017, the reporting person was granted 12,500 DSUs. The DSUs vested in full on June 27, 2018 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.

F2 · derivative.exercise_date: On December 15, 2017, the reporting person was granted 12,500 DSUs. The DSUs vested in full on June 27, 2018 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.

F2 · derivative.expiration_date: On December 15, 2017, the reporting person was granted 12,500 DSUs. The DSUs vested in full on June 27, 2018 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.

SEC source: 0000899243-18-018708 · doc4.xml · nonDerivative · entry 1

Godshall Douglas Evan · CIK 0001404227 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents vesting of deferred stock units ("DSUs") previously awarded to the reporting person, with each deferred stock unit representing the right to receive one share of the common stock of EyePoint Pharmaceuticals, Inc. (the "Company").

SEC source: 0000899243-18-018709 · doc4.xml · derivative · entry 2

ROGERS MICHAEL W · CIK 0001244159 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: On December 15, 2017, the reporting person was granted 12,500 DSUs. The DSUs vested in full on June 27, 2018 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.

F2 · derivative.exercise_date: On December 15, 2017, the reporting person was granted 12,500 DSUs. The DSUs vested in full on June 27, 2018 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.

F2 · derivative.expiration_date: On December 15, 2017, the reporting person was granted 12,500 DSUs. The DSUs vested in full on June 27, 2018 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.

SEC source: 0000899243-18-018709 · doc4.xml · nonDerivative · entry 1

ROGERS MICHAEL W · CIK 0001244159 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents vesting of deferred stock units ("DSUs") previously awarded to the reporting person, with each deferred stock unit representing the right to receive one share of the common stock of EyePoint Pharmaceuticals, Inc. (the "Company").

SEC source: 0000899243-18-018714 · doc4.xml · derivative · entry 2

Duker Jay S. · CIK 0001630864 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: On December 15, 2017, the reporting person was granted 12,500 DSUs. The DSUs vested in full on June 27, 2018 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.

F2 · derivative.exercise_date: On December 15, 2017, the reporting person was granted 12,500 DSUs. The DSUs vested in full on June 27, 2018 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.

F2 · derivative.expiration_date: On December 15, 2017, the reporting person was granted 12,500 DSUs. The DSUs vested in full on June 27, 2018 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.

SEC source: 0000899243-18-018714 · doc4.xml · nonDerivative · entry 1

Duker Jay S. · CIK 0001630864 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents vesting of deferred stock units ("DSUs") previously awarded to the reporting person, with each deferred stock unit representing the right to receive one share of the common stock of EyePoint Pharmaceuticals, Inc. (the "Company").

SEC source: 0000899243-18-018712 · doc4.xml · derivative · entry 2

Mazzo David J · CIK 0001334549 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 17,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: On December 15, 2017, the reporting person was granted 17,500 DSUs. The DSUs vested in full on June 27, 2018 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.

F2 · derivative.exercise_date: On December 15, 2017, the reporting person was granted 17,500 DSUs. The DSUs vested in full on June 27, 2018 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.

F2 · derivative.expiration_date: On December 15, 2017, the reporting person was granted 17,500 DSUs. The DSUs vested in full on June 27, 2018 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.

SEC source: 0000899243-18-018712 · doc4.xml · nonDerivative · entry 1

Mazzo David J · CIK 0001334549 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 138,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents vesting of deferred stock units ("DSUs") previously awarded to the reporting person, with each deferred stock unit representing the right to receive one share of the common stock of EyePoint Pharmaceuticals, Inc. (the "Company").

SEC source: 0000899243-18-018710 · doc4.xml · derivative · entry 3

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 10,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: On June 27, 2017, the reporting person was granted 30,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.

F2 · derivative.expiration_date: On June 27, 2017, the reporting person was granted 30,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.

SEC source: 0000899243-18-018710 · doc4.xml · nonDerivative · entry 2

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,388

F3 · shares: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the insider's exercise of his withholding right following the vesting of the restricted stock units.

SEC source: 0000899243-18-018710 · doc4.xml · nonDerivative · entry 1

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,333

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

SEC source: 0000899243-18-018295 · doc4.xml · derivative · entry 1

ANDO GORAN · CIK 0001110748 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2028-06-25

F1 · derivative.exercise_date: The option becomes exercisable in three equal annual installments beginning on June 25, 2019.

SEC source: 0000899243-18-019313 · doc4.xml · derivative · entry 4

EW Healthcare Partners, L.P. · CIK 0001612343 · 10% owner

EW Healthcare Partners-A, L.P. · CIK 0001736240 · 10% owner

Essex Woodlands Fund IX-GP, L.P. · CIK 0001652285 · 10% owner

Essex Woodlands IX, LLC · CIK 0001652286 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · EW Healthcare Partners-A L.P.

Disclosed balance after: 16,864,066

Underlying: Common Stock · 652,244 shares

Expires not disclosed

F3 · derivative.exercise_price: The exercise price of each of the warrants will be an amount equal to the lower of (a) $1.43 or (b) a 20% discount to the volume weighted average price of the shares of Common Stock on the Nasdaq Stock Market for the 20 trading days immediately prior to the exercise of a warrant; provided, however, that the exercise price cannot be lower than $0.88.

F1 · price: The purchase price is the price of one Unit ("Unit"), with each Unit consisting of (a) one share of common stock and (b) one warrant to purchase a share of common stock.

F4 · derivative.exercise_date: These securities are excercisable on or prior to the fifteenth (15) business day following the date on which EWHP and EWHP-A receive notice from the Issuer that the Centers for Medicare & Medicaid Services has announced that a new C-Code has been established for DexycuTM.

F4 · derivative.expiration_date: These securities are excercisable on or prior to the fifteenth (15) business day following the date on which EWHP and EWHP-A receive notice from the Issuer that the Centers for Medicare & Medicaid Services has announced that a new C-Code has been established for DexycuTM.

F5 · balance_after: Includes 16,211,864 warrant shares held by EWHP and 652,244 shares held EWHP-A. Fund IX-GP is the general partner of EWHP and EWHP-A, respectively. General Partner is the general partner of Fund IX-GP. The General Partner holds sole voting and dispositive power over the shares held by EWHP and EWHP-A. The Managers of the General Partner may exercise voting and investment control over the warrant shares only by the majority action of the Managers.

SEC source: 0000899243-18-019313 · doc4.xml · derivative · entry 3

EW Healthcare Partners, L.P. · CIK 0001612343 · 10% owner

EW Healthcare Partners-A, L.P. · CIK 0001736240 · 10% owner

Essex Woodlands Fund IX-GP, L.P. · CIK 0001652285 · 10% owner

Essex Woodlands IX, LLC · CIK 0001652286 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,864,066

Underlying: Common Stock · 16,211,822 shares

Expires not disclosed

F3 · derivative.exercise_price: The exercise price of each of the warrants will be an amount equal to the lower of (a) $1.43 or (b) a 20% discount to the volume weighted average price of the shares of Common Stock on the Nasdaq Stock Market for the 20 trading days immediately prior to the exercise of a warrant; provided, however, that the exercise price cannot be lower than $0.88.

F1 · price: The purchase price is the price of one Unit ("Unit"), with each Unit consisting of (a) one share of common stock and (b) one warrant to purchase a share of common stock.

F4 · derivative.exercise_date: These securities are excercisable on or prior to the fifteenth (15) business day following the date on which EWHP and EWHP-A receive notice from the Issuer that the Centers for Medicare & Medicaid Services has announced that a new C-Code has been established for DexycuTM.

F4 · derivative.expiration_date: These securities are excercisable on or prior to the fifteenth (15) business day following the date on which EWHP and EWHP-A receive notice from the Issuer that the Centers for Medicare & Medicaid Services has announced that a new C-Code has been established for DexycuTM.

F5 · balance_after: Includes 16,211,864 warrant shares held by EWHP and 652,244 shares held EWHP-A. Fund IX-GP is the general partner of EWHP and EWHP-A, respectively. General Partner is the general partner of Fund IX-GP. The General Partner holds sole voting and dispositive power over the shares held by EWHP and EWHP-A. The Managers of the General Partner may exercise voting and investment control over the warrant shares only by the majority action of the Managers.

SEC source: 0000899243-18-019313 · doc4.xml · nonDerivative · entry 2

EW Healthcare Partners, L.P. · CIK 0001612343 · 10% owner

EW Healthcare Partners-A, L.P. · CIK 0001736240 · 10% owner

Essex Woodlands Fund IX-GP, L.P. · CIK 0001652285 · 10% owner

Essex Woodlands IX, LLC · CIK 0001652286 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · EW Healthcare Partners-A L.P.

Disclosed balance after: 25,470,390

F1 · price: The purchase price is the price of one Unit ("Unit"), with each Unit consisting of (a) one share of common stock and (b) one warrant to purchase a share of common stock.

F2 · balance_after: Includes 24,485,283 shares held by EW Healthcare Partners L.P. ("EWHP") and 985,107 shares held by EW Healthcare Partners-A L.P. ("EWHP-A"). Essex Woodlands Fund IX-GP, L.P. ("Fund IX-GP") is the general partner of EWHP and EWHP-A, respectively. Essex Woodlands IX, LLC (the "General Partner") is the general partner of Fund IX-GP. The General Partner holds sole voting and dispositive power over the shares held by EWHP and EWHP-A. The managers of the General Partner are Martin P. Sutter, R. Scott Barry, Ronald Eastman (also a member of the Issuer's board of directors), Petri Vainio and Steve Wiggins (collectively, the "Managers"), and may exercise voting and investment control over the shares only by the majority action of the Managers.

F2 · ownership.direct: Includes 24,485,283 shares held by EW Healthcare Partners L.P. ("EWHP") and 985,107 shares held by EW Healthcare Partners-A L.P. ("EWHP-A"). Essex Woodlands Fund IX-GP, L.P. ("Fund IX-GP") is the general partner of EWHP and EWHP-A, respectively. Essex Woodlands IX, LLC (the "General Partner") is the general partner of Fund IX-GP. The General Partner holds sole voting and dispositive power over the shares held by EWHP and EWHP-A. The managers of the General Partner are Martin P. Sutter, R. Scott Barry, Ronald Eastman (also a member of the Issuer's board of directors), Petri Vainio and Steve Wiggins (collectively, the "Managers"), and may exercise voting and investment control over the shares only by the majority action of the Managers.

SEC source: 0000899243-18-019313 · doc4.xml · nonDerivative · entry 1

EW Healthcare Partners, L.P. · CIK 0001612343 · 10% owner

EW Healthcare Partners-A, L.P. · CIK 0001736240 · 10% owner

Essex Woodlands Fund IX-GP, L.P. · CIK 0001652285 · 10% owner

Essex Woodlands IX, LLC · CIK 0001652286 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,470,390

F1 · price: The purchase price is the price of one Unit ("Unit"), with each Unit consisting of (a) one share of common stock and (b) one warrant to purchase a share of common stock.

F2 · balance_after: Includes 24,485,283 shares held by EW Healthcare Partners L.P. ("EWHP") and 985,107 shares held by EW Healthcare Partners-A L.P. ("EWHP-A"). Essex Woodlands Fund IX-GP, L.P. ("Fund IX-GP") is the general partner of EWHP and EWHP-A, respectively. Essex Woodlands IX, LLC (the "General Partner") is the general partner of Fund IX-GP. The General Partner holds sole voting and dispositive power over the shares held by EWHP and EWHP-A. The managers of the General Partner are Martin P. Sutter, R. Scott Barry, Ronald Eastman (also a member of the Issuer's board of directors), Petri Vainio and Steve Wiggins (collectively, the "Managers"), and may exercise voting and investment control over the shares only by the majority action of the Managers.

F2 · ownership.direct: Includes 24,485,283 shares held by EW Healthcare Partners L.P. ("EWHP") and 985,107 shares held by EW Healthcare Partners-A L.P. ("EWHP-A"). Essex Woodlands Fund IX-GP, L.P. ("Fund IX-GP") is the general partner of EWHP and EWHP-A, respectively. Essex Woodlands IX, LLC (the "General Partner") is the general partner of Fund IX-GP. The General Partner holds sole voting and dispositive power over the shares held by EWHP and EWHP-A. The managers of the General Partner are Martin P. Sutter, R. Scott Barry, Ronald Eastman (also a member of the Issuer's board of directors), Petri Vainio and Steve Wiggins (collectively, the "Managers"), and may exercise voting and investment control over the shares only by the majority action of the Managers.

SEC source: 0000899243-18-018100 · doc4.xml · derivative · entry 3

Peterson Kristine · CIK 0001508596 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2028-06-21

F3 · derivative.exercise_date: The option becomes exercisable in two equal annual installments beginning on June 21, 2019.

SEC source: 0000899243-18-018100 · doc4.xml · derivative · entry 2

Peterson Kristine · CIK 0001508596 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,667

Underlying: Common Stock · 6,667 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents the right to receive one share of the common stock of EyePoint Pharmaceuticals, Inc. (the "Company").

F2 · derivative.expiration_date: Subsequent to the vesting of the deferred stock units, the deferred stock units will be settled in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.

SEC source: 0000899243-18-018100 · doc4.xml · derivative · entry 1

Peterson Kristine · CIK 0001508596 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,667

Underlying: Common Stock · 26,667 shares

Expires 2028-06-21

SEC source: 0000899243-18-018095 · doc4.xml · derivative · entry 2

Godshall Douglas Evan · CIK 0001404227 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,667

Underlying: Common Stock · 6,667 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents the right to receive one share of the common stock of EyePoint Pharmaceuticals, Inc. (the "Company").

F2 · derivative.expiration_date: Subsequent to the vesting of the deferred stock units, the deferred stock units will be settled in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.

SEC source: 0000899243-18-018095 · doc4.xml · derivative · entry 1

Godshall Douglas Evan · CIK 0001404227 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,667

Underlying: Common Stock · 26,667 shares

Expires 2028-06-21

SEC source: 0000899243-18-018096 · doc4.xml · derivative · entry 2

ROGERS MICHAEL W · CIK 0001244159 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,667

Underlying: Common Stock · 6,667 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents the right to receive one share of the common stock of EyePoint Pharmaceuticals, Inc. (the "Company").

F2 · derivative.expiration_date: Subsequent to the vesting of the deferred stock units, the deferred stock units will be settled in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.

SEC source: 0000899243-18-018096 · doc4.xml · derivative · entry 1

ROGERS MICHAEL W · CIK 0001244159 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,667

Underlying: Common Stock · 26,667 shares

Expires 2028-06-21

SEC source: 0000899243-18-018098 · doc4.xml · derivative · entry 2

Duker Jay S. · CIK 0001630864 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,667

Underlying: Common Stock · 6,667 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents the right to receive one share of the common stock of EyePoint Pharmaceuticals, Inc. (the "Company").

F2 · derivative.expiration_date: Subsequent to the vesting of the deferred stock units, the deferred stock units will be settled in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.

SEC source: 0000899243-18-018098 · doc4.xml · derivative · entry 1

Duker Jay S. · CIK 0001630864 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,667

Underlying: Common Stock · 26,667 shares

Expires 2028-06-21

SEC source: 0000899243-18-018093 · doc4.xml · derivative · entry 2

Mazzo David J · CIK 0001334549 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,333

Underlying: Common Stock · 8,333 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents the right to receive one share of the common stock of EyePoint Pharmaceuticals, Inc. (the "Company").

F2 · derivative.expiration_date: Subsequent to the vesting of the deferred stock units, the deferred stock units will be settled in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.

SEC source: 0000899243-18-018093 · doc4.xml · derivative · entry 1

Mazzo David J · CIK 0001334549 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,333

Underlying: Common Stock · 33,333 shares

Expires 2028-06-21

SEC source: 0000899243-18-016975 · doc4.xml · derivative · entry 2

Ross Leonard S · CIK 0001458753 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,100

Underlying: Common Stock · 85,100 shares

Expires 2028-06-14

F3 · derivative.exercise_date: The option to purchase will vest and become exercisable in three equal annual installments beginning June 14, 2019.

SEC source: 0000899243-18-016975 · doc4.xml · derivative · entry 1

Ross Leonard S · CIK 0001458753 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,300

Underlying: Common Stock · 21,300 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock.

F2 · derivative.exercise_date: The restricted stock units will vest in three equal annual installments beginning June 14, 2019. Vested shares will be delivered to the reporting person within 30 days following each respective vesting date.

F2 · derivative.expiration_date: The restricted stock units will vest in three equal annual installments beginning June 14, 2019. Vested shares will be delivered to the reporting person within 30 days following each respective vesting date.

SEC source: 0000899243-18-016980 · doc4.xml · derivative · entry 2

Lurker Nancy · CIK 0001450485 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 540,000

Underlying: Common Stock · 540,000 shares

Expires 2028-06-14

F3 · derivative.exercise_date: The option to purchase will vest and become exercisable in three equal annual installments beginning June 14, 2019.

SEC source: 0000899243-18-016980 · doc4.xml · derivative · entry 1

Lurker Nancy · CIK 0001450485 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 135,000

Underlying: Common Stock · 135,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock.

F2 · derivative.exercise_date: The restricted stock units will vest in three equal annual installments beginning June 14, 2019. Vested shares will be delivered to the reporting person within 30 days following each respective vesting date.

F2 · derivative.expiration_date: The restricted stock units will vest in three equal annual installments beginning June 14, 2019. Vested shares will be delivered to the reporting person within 30 days following each respective vesting date.

SEC source: 0000899243-18-016986 · doc4.xml · derivative · entry 2

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 170,500

Underlying: Common Stock · 170,500 shares

Expires 2028-06-14

F3 · derivative.exercise_date: The option to purchase will vest and become exercisable in three equal annual installments beginning June 14, 2019.

SEC source: 0000899243-18-016986 · doc4.xml · derivative · entry 1

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,600

Underlying: Common Stock · 42,600 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock.

F2 · derivative.exercise_date: The restricted stock units will vest in three equal annual installments beginning June 14, 2019. Vested shares will be delivered to the reporting person within 30 days following each respective vesting date.

F2 · derivative.expiration_date: The restricted stock units will vest in three equal annual installments beginning June 14, 2019. Vested shares will be delivered to the reporting person within 30 days following each respective vesting date.

SEC source: 0000899243-18-017684 · doc4a.xml · derivative · entry 2

Ross Leonard S · CIK 0001458753 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,360

Underlying: Common Stock · 99,360 shares

Expires 2028-06-14

F3 · derivative.exercise_date: The option to purchase will vest and become exercisable in three equal annual installments beginning June 14, 2019.

SEC source: 0000899243-18-017684 · doc4a.xml · derivative · entry 1

Ross Leonard S · CIK 0001458753 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,840

Underlying: Common Stock · 24,840 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock.

F2 · derivative.exercise_date: The restricted stock units will vest in three equal annual installments beginning June 14, 2019. Vested shares will be delivered to the reporting person within 30 days following each respective vesting date.

F2 · derivative.expiration_date: The restricted stock units will vest in three equal annual installments beginning June 14, 2019. Vested shares will be delivered to the reporting person within 30 days following each respective vesting date.

SEC source: 0000899243-18-013140 · doc4.xml · derivative · entry 2

BLUM LEONARD M · CIK 0001222247 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2028-05-14

F2 · derivative.exercise_date: The option to purchase will vest and become exercisable in full on May 14, 2019.

SEC source: 0000899243-18-013140 · doc4.xml · derivative · entry 1

BLUM LEONARD M · CIK 0001222247 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 375,000

Underlying: Common Stock · 375,000 shares

Expires 2028-05-14

F1 · derivative.exercise_date: The option to purchase will vest and become exercisable in three equal annual installments beginning May 14, 2019.

SEC source: 0000899243-18-012670 · doc4.xml · derivative · entry 2

Barry James J · CIK 0001541253 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each deferred stock unit represents the right to receive one share of the common stock of EyePoint Pharmaceuticals, Inc.

F2 · derivative.exercise_date: On December 15, 2017, the reporting person was granted 12,500 deferred stock units, which deferred stock units vested in full in connection with the effectiveness of Mr. Barry's resignation from the Board on May 7, 2018.

F2 · derivative.expiration_date: On December 15, 2017, the reporting person was granted 12,500 deferred stock units, which deferred stock units vested in full in connection with the effectiveness of Mr. Barry's resignation from the Board on May 7, 2018.

SEC source: 0000899243-18-012670 · doc4.xml · nonDerivative · entry 1

Barry James J · CIK 0001541253 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each deferred stock unit represents the right to receive one share of the common stock of EyePoint Pharmaceuticals, Inc.

SEC source: 0000899243-18-010649 · doc4.xml · derivative · entry 2

Mazzo David J · CIK 0001334549 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 120,000 shares

Expires 2018-11-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-18-010649 · doc4.xml · nonDerivative · entry 1

Mazzo David J · CIK 0001334549 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 120,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.